If you haven`t bought SRPT here: Then you need to know that there is a Massive catalyst coming! Sarepta Therapeutics is going to announce Duchenne muscular dystrophy Phase 3 data for its SRP-9001-301 - (EMBARK) by mid November. This week institutions bought calls worth more than $10Mil that SRPT Sarepta Therapeutics will trade above $135 by November 17. Some...
Looking at the SRPT Sarepta Therapeutics options chain, i would buy the $125 calls with 2023-2-17 expiration date for about $7.10 premium. Looking forward to read your opinion about it.
$SPRT is about to break the resistance of cup after a long consolidation. There are two options in front; one ise to break and to continue rising and the other one is forming a handle. If you find my charts useful, please just leave me a "Like" thx